Advance More Personalized Therapies for Rare and Common Kidney Diseases The surge of clinical breakthroughs in SGLT2s, GLP-1s and ERAs for CKD, significant advancements to...

Determining MoA and Satisfying Regulatory Requirements In the dynamic cell therapy landscape, the challenge of potency assay development looms large, as exemplified by clinical...

Not that much time has passed since our last summit. But a lot has changed. From 2023 to 2024, the industry has made unequivocal advances, from tangible progress using...

The 4ᵗʰ Wet AMD and Diabetic Eye Disease Drug Development Summit is returning to Boston this March to unite 70+ industry-based retinal vascular experts from the likes of Bayer,...

Following the increasing interest in access to investigational medicines from patients, the harmonization of guidance and research on the value of expanded access programs...